In today’s briefing:
- Wuxi Biologics (2269.HK) – Dramatic Changes in Management Forecasts Fail to Bring Back Confidence
- Sumitomo Pharma (4506 JP): FY24 Guidance Seems to Be Aggressive; Downtrend Will Likely To Continue
- Vanda Pharmaceuticals Inc. (VNDA) – Sunday, Oct 15, 2023
![](http://www.smartkarma.com/assets/plugins/a3-lazy-load/assets/images/lazy_placeholder.gif)
Wuxi Biologics (2269.HK) – Dramatic Changes in Management Forecasts Fail to Bring Back Confidence
- WuXi Bio’s optimism about new orders failed to generated expected surge in its stock price. Many investors raised great doubts about the credibility and professionalism in communication of WuXi Bio.
- It’s easy/cost-effective for WuXi Bio to “adjust” order number. However, it’s more difficult to inflate revenue/cash flow. We have to wait for future financial results to know the real situation.
- XBI is essentially “a bond”.Recent surge of XBI is driven by the expectations of Fed’s rate cut + US soft landing, rather than virtual improvement of external environment.Much remains unclear.
Sumitomo Pharma (4506 JP): FY24 Guidance Seems to Be Aggressive; Downtrend Will Likely To Continue
- Sumitomo Pharma (4506 JP) still expects FY24 revenue of ¥362 billion (down 35% YoY). This implies H2FY24 revenue of ¥209.4 billion, up 37% compared with H1FY24.
- To achieve this target, North America needs to perform strongly. H1FY24 revenue from North America has shown a progress rate of just 35% against full-year FY24 revenue guidance.
- With the absence of any strong catalyst, we expect recent rally in Sumitomo shares fueled by encouraging clinical trial result and new drug approval in China, will be short-lived.
Vanda Pharmaceuticals Inc. (VNDA) – Sunday, Oct 15, 2023
Key points (machine generated)
- Vanda Pharmaceuticals has established revenue-generating drugs and a pipeline of potential candidates in development.
- The company has a strong balance sheet with ample cash reserves, offering potential for investments or acquisitions.
- Despite these positive traits, the market values Vanda as if its core business is worthless, presenting a potential investment opportunity with significant upside potential.
This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.